Abstract
In this article, our activatable (non-DDS) rapid fluorescent probes are showcased, which were developed by utilizing our original precise design strategies for fluorescent probes, and whose fluorescence characteristics are greatly altered only in the cancer site. Some of the developed probes have been found to be sufficiently effective in treating spontaneous cancers of actual patients beyond the level of animal experiments, and clinical development of several probes for use in actual clinical practice has been started, including the first in human study. It is highly anticipated that the day will soon come when surgeons will be able to clearly identify the site of cancer to be treated and will be able to perform precise fluorescence endoscopic or open surgery. This article also briefly summarizes the author's thoughts on the future of cancer care technology using a combination of non-DDS probe and DDS technologies.
